Regulation Policy for Cell and Tissue Therapies in Australia
- PMID: 26096750
- DOI: 10.1089/ten.TEA.2014.0576
Regulation Policy for Cell and Tissue Therapies in Australia
Abstract
In Australia, therapeutic goods are regulated by the Australian Government through the Therapeutic Goods Administration. In recent times, there have been significant changes to legislative instruments to accommodate the emergence of biotherapies, and a new regulatory framework was implemented in 2013. Therapeutic goods are regulated as medicines, devices, or biologics. With some exemptions and exceptions, human cellular and tissue products are regulated as biologics. The new regulation has taken a risk-based approach, with the level of regulation reflecting the perceived risk of the product, and products are classified from class 1 (low risk) to class 4 (highest risk). Other than for class 1 products, manufacturers must demonstrate conformance with the Australian Code of Good Manufacturing Practice and compliance with relevant Therapeutic Goods Orders and Standards through the submission of dossiers. The higher the classification of product, the more rigorous the dossier requirements. Listing of products on the Australian Therapeutic Goods Register is required for all products with some exceptions. The new regulatory framework provides greater clarity for manufacturers and strives to harmonize with international standards.
Similar articles
-
Raising the standard: changes to the Australian Code of Good Manufacturing Practice (cGMP) for human blood and blood components, human tissues and human cellular therapy products.Pathology. 2014 Apr;46(3):177-83. doi: 10.1097/PAT.0000000000000067. Pathology. 2014. PMID: 24614714 Review.
-
Regulation of cellular therapy in Australia.Pathology. 2011 Oct;43(6):627-34. doi: 10.1097/PAT.0b013e32834b3cfa. Pathology. 2011. PMID: 21897330 Review.
-
Regulation of cellular therapies: the Australian perspective.Cytotherapy. 2003;5(4):284-8. doi: 10.1080/14653240310002207. Cytotherapy. 2003. PMID: 12944233 Review.
-
Regulation of Cell- and Tissue-Based Therapeutic Products in Singapore.Tissue Eng Part A. 2015 Dec;21(23-24):2802-5. doi: 10.1089/ten.TEA.2014.0712. Epub 2015 Jul 23. Tissue Eng Part A. 2015. PMID: 26096855
-
Clinical Translation of Cell Therapy, Tissue Engineering, and Regenerative Medicine Product in Malaysia and Its Regulatory Policy.Tissue Eng Part A. 2015 Dec;21(23-24):2812-6. doi: 10.1089/ten.TEA.2014.0521. Epub 2015 Aug 21. Tissue Eng Part A. 2015. PMID: 26192075 Free PMC article.
Cited by
-
Lifelike Transformative Materials for Biohybrid Implants: Inspired by Nature, Driven by Technology.Adv Healthc Mater. 2023 Aug;12(20):e2300991. doi: 10.1002/adhm.202300991. Epub 2023 Jun 8. Adv Healthc Mater. 2023. PMID: 37290055 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
